ClinicalTrials.gg
CompletedNCT02119156Updated Jan 31, 2020Results posted

Belimumab Treatment Holiday and Treatment Re-start Study in Lupus Patients

A Phase 3 interventional study of Belimumab in Systemic Lupus Erythematosus, sponsored by GlaxoSmithKline. Completed at 20 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-01-31.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
80
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 36 studies testing belimumab in Lupus Erythematosus, Systemic — 4 open to participants now, 7 under way, none of them phase 3. belimumab · Lupus Erythematosus, Systemic.

Enrollment
19th of 36
80 · median 81
Started
2014
with 2 others
Phase 3
11 of 36
none open now
Registered
20th of 36
by date
Lead sponsor
13 of 36
GlaxoSmithKline

Among the 36 studies testing belimumab in Lupus Erythematosus, Systemic, this one is the 19th largest by enrollment, is one of 3 that started in 2014, is one of 11 in phase 3, and was the 20th registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

4 of the 36 studies testing belimumab in Lupus Erythematosus, Systemic are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About belimumab

belimumab: first FDA approval 2011 (BENLYSTA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing belimumab in Lupus Erythematosus, Systemic, or all of them as a file.
02

Study summary

This study will assess the effect of a 24-week withdrawal followed by a 28-week reintroduction of belimumab 10 mg/kg plus standard of care medications in subjects with stable low systemic lupus erythematosus (SLE) disease activity. Rebound phenomenon will be assessed for subjects who have permanently withdrawn from further belimumab treatment.

Read the detailed description

This study will assess the effect of a 24-week withdrawal of belimumab followed by a 28-week reintroduction of belimumab 10 mg/kg plus standard of care medications on immunogenicity, markers of biological activity, efficacy, and safety in subjects with stable low systemic lupus erythematosus (SLE) disease activity. Additionally, this study will assess rebound phenomenon in subjects with any disease level of SLE who have permanently withdrawn from further belimumab treatment

03

Conditions studied

  • Systemic Lupus Erythematosus

Keywords

  • treatment holiday
  • PGA
  • belimumab
  • Lymphostat-B
  • rebound
  • SELENA SLEDAI
  • Systemic Lupus Erythematosus
  • immunogenicity
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Received a minimun of 6 months therapy with with belimumab 10 mg/kg in their current SLE belimumab continuation study.
  • Be 18 years of age at the Day 0 visit.
  • Non-prenant, non-lactating females willing to comply with specific requirements as set forth in the protocol.
  • Able to provide written to participate.
  • Subjects who wish to enroll in the control group and the group taking a 6 month belimumab treatment holiday will need a SELENA SLEDAI score of 3 or less after the minimum of 6 months belimumab therapy, as well as having C3 and C4 complement levels at or above the lower limit of the central laboratory reference range, and are on a stable SLE treatment regimen during the 30 day screening period prior to Day 0.
  • Subjects who wish to enroll in the long-term discontinuation group have voluntarily withdrawn from their continuation studies.

Exclusion criteria

Exclusion Criteria:

  • Subjects who have developed clinical evidence of significant, unstable or uncontrolled, acute or chronic diseases not due to SLE, or experienced an adverse event (AE) in their belimumab continuation study that could, in the opinion of the principle investigator, put the subject at undue risk.
  • Subjects who have developed any other medical diseases, laboratory abnormalities, or conditions that, in the opinion of the principle investigator, makes the subject unsuitable for the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    Treatment Holiday Group

    Subjects in the Treatment Holiday Group will undergo a 6 month belimumab treatment holiday while remaining on standard of care SLE therapy, then re-start belimumab therapy for 6 months while receiving standard of care SLE therapy.

    Drug: Belimumab

  • Active comparator
    Control Group

    Subjects in the Control Group will continue to receive monthly belimumab therapy, in addition to standard of care SLE therapy for 52 weeks.

    Drug: Belimumab

  • No intervention
    Long-Term Discontinuation Group

    Subjects in the Long-Term Discontinuation Group have elected to discontinue further belimumab therapy and will remain on standard of care SLE therapy as directed by the investigator, and agree to return for monthly visits for 52 weeks.

Interventions

  • Monthly intravenous infusions dosed as 10 mg/kg body weight

06

What researchers measure

Primary outcomes

  1. Median Time to First SLE Flare Index (SFI)

    SFI Flare was defined as a mild/moderate or severe flare according to the modified Safety of Estrogen in Lupus National Assessment Systemic Lupus Erythematosus Disease Activity Index (SELENA SLEDAI) SLE Flare Index (modified excluded severe flares from the SELENA SLEDAI flare assessment that were triggered only by an increase in SELENA SLEDAI score to \>12).Time to first SFI flare is defined as the number of days from Day 0 visit date to the date the participant has a flare (event date - Day 0 visit date + 1) in the 52 Week/Holiday phase; (event date - treatment re-start date + 1) in the Re-start Holiday phase. Day 0 visit date is defined as Day 0 from present study. Median time to first SFI flare is reported; estimated using the product-limit method.

    Time frame: Up to 52 weeks

Secondary outcomes

  1. Rate of SLE Index Flare Per Subject Year

    Rate per subject year of SFI flare was calculated as total number of flares divided by total subject years in interval. The total subject years for each participant was calculated as (Week 52/ Exit visit date minus Day 0 visit date + 1) for Long-term discontinuation and treatment control groups. For treatment holiday phase group the subject-years for each participant was calculated as (Week 24/Treatment Re-start/Exit visit date minus Day 0 Visit date + 1)/365.25. For re-start treatment holiday phase group the subject-years for each participant was calculated as (Week 52/Exit visit date minus Week 24/Treatment Re-start date + 1)/365.25. Day 0 visit date is defined as Day 0 from present study.

    Time frame: Up to 52 weeks

  2. Median Time to First Severe SFI Flare

    The SLE Flare Index categorizes SLE flare as "mild or moderate" or "severe" based on a positive assessment for at least 1 of 5 variables as follows: Change in SELENA SLEDAI score from the most recent assessment to current; Change in signs or symptoms of disease activity; Change in prednisone dosage; Use of new medications for disease activity or hospitalization; Change in Physician's Global Assessment (PGA) score; Hospitalization for SLE activity is an additional category included only for a severe flare. Time to first severe flare is defined as (event date-Day 0 visit date) + 1 for Long-term discontinuation, treatment control groups and holiday phase group. For holiday phase group data censored at last flare assessment by treatment re-start date. Time to first severe flare is defined as (event date-treatment re-start date) + 1 for Re-start treatment holiday group. Median time to first severe SFI flare is reported; estimated using the product-limit method.

    Time frame: Up to 52 weeks

  3. Number of Participants With Evidence of Rebound

    Rebound is defined as SELENA SLEDAI score during the first 24 weeks that exceeds the Baseline SELENA SLEDAI score in the participant's respective original parent study. Baseline is defined as the Day 0 visit from the parent study. SELENA SLEDAI assessments consist of 24 individual weighted items in which signs and symptoms, laboratory tests, and physician's assessment for each of 9 organ systems are given a weighted score and summed if present (marked 'Yes') at the time of the visit or in the preceding 10 days. The maximum theoretical score is 105 (all 24 descriptors present simultaneously) with 0 indicating inactive disease (marked 'No'). Any time during the first 24 weeks of this study has been reported.

    Time frame: Up to 24 weeks

  4. Number of Participants With Confirmed True Positive Belimumab Anti-drug Antibodies (ADA)

    Immunogenicity assay results were categorized as negative or positive. A persistent positive result was defined as a positive post-Day 0 visit immunogenic response that occurred for at least 2 consecutive assessments or a single result at the final assessment. A transient positive result was defined as a single post-Day 0 visit positive immunogenic response that did not occur at the final assessment. Any time post-Day 0 visit data are reported (or post-Week 24 for Treatment Holiday - Restart phase). Day 0 visit date is defined as Day 0 from present study.

    Time frame: Up to 52 weeks

  5. Percentage Change From Baseline in Immunoglobulin

    Serum samples were collected at indicated time-points for analysis of immunoglobulins: Immunoglobulin G (IgG), Immunoglobulin A (IgA), and Immunoglobulin M (IgM). Baseline is defined as the Day 0 visit from parent studies. Percentage change from Baseline is equal to 100\* (value at specified visit minus Baseline value) divided by Baseline value.

    Time frame: Baseline (Day 0 from parent studies); Day 0 and 8, 16, 24, 32, 40, 48 and 52 weeks

  6. Percentage Change From Baseline in Autoantibody:Anti-double Stranded Deoxyribonucleic Acid (dsDNA)

    Blood samples were collected at indicated time-points for analysis of autoantibodies like dsDNA. Baseline is defined as the Day 0 visit from parent studies. Percentage change from Baseline is equal to 100\* (Value at specified visit minus Baseline value) divided by Baseline value.

    Time frame: Baseline (Day 0 from parent studies); Day 0 and 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52 weeks

  7. Percentage Change From Baseline in Autoantibody: Antinuclear Antibody (ANA)

    Blood samples were collected at indicated time-points for analysis of autoantibodies like ANA. Only participants who had an ANA value measured in INDEX at the parent studies Baseline were included in this analysis. Baseline is defined as the Day 0 visit from parent studies. Percentage change from Baseline is equal to 100\* (Value at specified visit minus Baseline value) divided by Baseline value.

    Time frame: Baseline (Day 0 from parent studies); Day 0 and 24 and 52 weeks

  8. Percentage Change From Baseline in Complement Levels

    Blood samples were collected at indicated time-points for analysis of complement levels like complement 3 (C3) and complement 4 (C4). Baseline is defined as the Day 0 visit from parent studies. Percentage change from Baseline is equal to 100\* (Value at specified visit minus Baseline value) divided by Baseline value.

    Time frame: Baseline (Day 0 from parent studies); Day 0 and 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52 weeks

  9. Percentage Change From Baseline in B Cell Subsets

    Blood samples were collected at indicated time-points for analysis of Activated B cells subsets like Activated CD19+CD20+CD69+, cluster of differentiation 20+ (CD20+), Memory CD19+CD20+CD27+, Naive CD19+CD20+CD27-, Plasma CD19+CD20-CD138+, Plasmacytoid CD19+CD20+CD138+, and SLE Subset CD19+CD38b+CD27b+Lymph. Baseline is defined as the Day 0 visit from parent studies. Percentage change from Baseline is equal to 100\* (Value at specified visit minus Baseline value) divided by Baseline value.

    Time frame: Baseline (Day 0 from parent studies); Day 0 and 8, 16, 24, 32, 40 and 52 weeks

  10. Percentage Change From 24 Week in B Cell Subsets: Treatment Holiday Group (Re-start Phase)

    Blood samples were collected at indicated time-points for analysis of Activated B cells subsets like Activated CD19+CD20+CD69+, CD20+, Memory CD19+CD20+CD27+, Naive CD19+CD20+CD27-, Plasma CD19+CD20-CD138+, Plasmacytoid CD19+CD20+CD138+, and SLE Subset CD19+CD38b+CD27b+Lymph. Percentage change from Week 24 of present study was calculated as 100\*(value at specified visit - Week 24 value) divided by week 24 value. The data below is only reported for the Treatment Holiday Group (Re-start phase). Participants in this group restarted belimumab therapy one day after Week 24, hence the Baseline for this outcome measure was Week 24 visit. No other groups were measured for this outcome.

    Time frame: Week 24, 32, 40 and 52 weeks

  11. SELENA SLEDAI Scores Change From Baseline

    SELENA SLEDAI assessments consist of 24 individual weighted items in which signs and symptoms, laboratory tests, and physician's assessment for each of 9 organ systems are given a weighted score and summed if present (marked 'Yes') at the time of the visit or in the preceding 10 days. The maximum theoretical score is 105 (all 24 descriptors present simultaneously) with 0 indicating inactive disease (marked 'No'). Data are reported at the specified time-points from Day 0 (of present study) up to Week 52. Baseline is defined as the Day 0 from parent studies. Change from Baseline is equal to (Value at specified visit minus Baseline value).

    Time frame: Baseline (Day 0 from parent studies); Day 0 and 4, 8, 12, 16, 20, 24, 28, 32,36, 40, 44, 48 and 52 weeks

  12. Number of Days of Daily Prednisone Dose >=7.5 mg/Day and/or Increased by 25 Percent From Day 0 of This Study

    All corticosteroids are converted to a prednisone equivalent average daily dose (mg/day). The average daily dose at Day 0 was used to assess the relative change in daily dose on a given day. The average daily dose at Day 0 was calculated as sum of the daily dose across all days from the Screening visit date up to and including Day 0 visit date divided by the number of days in the time period. Data reported are the median number of days on which the specified criteria was met for Day 0 to Week 24, Week 24 to Week 52, Day 0 to Week 52. For treatment holiday group, Day 0 to Week 24 corresponds to holiday phase, Week 24 to Week 52 corresponds to treatment Re-start phase.

    Time frame: Day 0 to Week 24; Week 24 to Week 52; Day 0 to Week 52

  13. Number of Days of Daily Prednisone Dose <=7.5 mg/Day and/or Decreased by 25 Percent From Day 0 of This Study

    All corticosteroids are converted to a prednisone equivalent average daily dose (mg/day). The average daily dose at Day 0 was used to assess the relative change in daily dose on a given day. The average daily dose at Day 0 was calculated as sum of the daily dose across all days from the Screening visit date up to and including Day 0 visit date divided by the number of days in the time period. Data reported are the median number of days on which the specified criteria was met for Day 0 to Week 24, Week 24 to Week 52, Day 0 to Week 52. For treatment holiday group, Day 0 to Week 24 corresponds to holiday phase, Week 24 to Week 52 corresponds to treatment Re-start phase.

    Time frame: Day 0 to Week 24; Week 24 to Week 52; Day 0 to Week 52

07

Results

Posted Jan 31, 2020
Limitations and caveats
Study limitations include the small sample size and differences in Day 0 characteristics between Long-term Discontinuation and Treatment Control groups, which limits the ability to draw inferences.

Participant flow

This was multi-center study to evaluate temporary discontinuation of belimumab 10 milligram(mg)/kilogram(kg) for 24 weeks followed by reintroduction of belimumab 10 mg/kg Intravenous (IV) for 28 weeks, in participants with low Systemic Lupus Erythematosus (SLE) disease activity receiving belimumab plus standard of care.

Treatment Phase (Up to 52 Weeks)
Participant flow — Treatment Phase (Up to 52 Weeks)
MilestoneLong-term Discontinuation GroupTreatment Control GroupTreatment Holiday Group
Started392912
Completed332711
Not completed621
Withdrew: Study terminated by sponsor001
Withdrew: Withdrawal by subject400
Withdrew: Protocol violation120
Withdrew: Physician decision100
Maintenance (Up to 48 Weeks of Year 2-4)
Participant flow — Maintenance (Up to 48 Weeks of Year 2-4)
MilestoneLong-term Discontinuation GroupTreatment Control GroupTreatment Holiday Group
Started01610
Completed063
Not completed0107
Withdrew: Study terminated by sponsor0107

Outcome measures

PrimaryMedian Time to First SLE Flare Index (SFI)

SFI Flare was defined as a mild/moderate or severe flare according to the modified Safety of Estrogen in Lupus National Assessment Systemic Lupus Erythematosus Disease Activity Index (SELENA SLEDAI) SLE Flare Index (modified excluded severe flares from the SELENA SLEDAI flare assessment that were triggered only by an increase in SELENA SLEDAI score to \>12).Time to first SFI flare is defined as the number of days from Day 0 visit date to the date the participant has a flare (event date - Day 0 visit date + 1) in the 52 Week/Holiday phase; (event date - treatment re-start date + 1) in the Re-start Holiday phase. Day 0 visit date is defined as Day 0 from present study. Median time to first SFI flare is reported; estimated using the product-limit method.

Time frame:
Up to 52 weeks
Reported as:
Median · Days
Median Time to First SLE Flare Index (SFI)
DaysLong-term Discontinuation GroupTreatment Control GroupTreatment Holiday Group - Holiday PhaseTreatment Holiday Group - Re-start Phase
Median Time to First SLE Flare Index (SFI)183.0 (91.0 to 370.0)NA (365.0 to NA)NA (30.0 to NA)NA (NA to NA)
SecondaryRate of SLE Index Flare Per Subject Year

Rate per subject year of SFI flare was calculated as total number of flares divided by total subject years in interval. The total subject years for each participant was calculated as (Week 52/ Exit visit date minus Day 0 visit date + 1) for Long-term discontinuation and treatment control groups. For treatment holiday phase group the subject-years for each participant was calculated as (Week 24/Treatment Re-start/Exit visit date minus Day 0 Visit date + 1)/365.25. For re-start treatment holiday phase group the subject-years for each participant was calculated as (Week 52/Exit visit date minus Week 24/Treatment Re-start date + 1)/365.25. Day 0 visit date is defined as Day 0 from present study.

Time frame:
Up to 52 weeks
Reported as:
Number · Flares per Subject-year
Rate of SLE Index Flare Per Subject Year
Flares per Subject-yearLong-term Discontinuation GroupTreatment Control GroupTreatment Holiday Group - Holiday PhaseTreatment Holiday Group - Re-start Phase
Rate of SLE Index Flare Per Subject Year2.10.61.00.3
SecondaryMedian Time to First Severe SFI Flare

The SLE Flare Index categorizes SLE flare as "mild or moderate" or "severe" based on a positive assessment for at least 1 of 5 variables as follows: Change in SELENA SLEDAI score from the most recent assessment to current; Change in signs or symptoms of disease activity; Change in prednisone dosage; Use of new medications for disease activity or hospitalization; Change in Physician's Global Assessment (PGA) score; Hospitalization for SLE activity is an additional category included only for a severe flare. Time to first severe flare is defined as (event date-Day 0 visit date) + 1 for Long-term discontinuation, treatment control groups and holiday phase group. For holiday phase group data censored at last flare assessment by treatment re-start date. Time to first severe flare is defined as (event date-treatment re-start date) + 1 for Re-start treatment holiday group. Median time to first severe SFI flare is reported; estimated using the product-limit method.

Time frame:
Up to 52 weeks
Reported as:
Median · Days
Median Time to First Severe SFI Flare
DaysLong-term Discontinuation GroupTreatment Control GroupTreatment Holiday Group - Holiday PhaseTreatment Holiday Group - Re-start Phase
Median Time to First Severe SFI FlareNA (327.0 to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)
SecondaryNumber of Participants With Evidence of Rebound

Rebound is defined as SELENA SLEDAI score during the first 24 weeks that exceeds the Baseline SELENA SLEDAI score in the participant's respective original parent study. Baseline is defined as the Day 0 visit from the parent study. SELENA SLEDAI assessments consist of 24 individual weighted items in which signs and symptoms, laboratory tests, and physician's assessment for each of 9 organ systems are given a weighted score and summed if present (marked 'Yes') at the time of the visit or in the preceding 10 days. The maximum theoretical score is 105 (all 24 descriptors present simultaneously) with 0 indicating inactive disease (marked 'No'). Any time during the first 24 weeks of this study has been reported.

Time frame:
Up to 24 weeks
Reported as:
Count of participants · Participants
Number of Participants With Evidence of Rebound
ParticipantsLong-term Discontinuation GroupTreatment Control GroupTreatment Holiday Group
Number of Participants With Evidence of Rebound220
SecondaryNumber of Participants With Confirmed True Positive Belimumab Anti-drug Antibodies (ADA)

Immunogenicity assay results were categorized as negative or positive. A persistent positive result was defined as a positive post-Day 0 visit immunogenic response that occurred for at least 2 consecutive assessments or a single result at the final assessment. A transient positive result was defined as a single post-Day 0 visit positive immunogenic response that did not occur at the final assessment. Any time post-Day 0 visit data are reported (or post-Week 24 for Treatment Holiday - Restart phase). Day 0 visit date is defined as Day 0 from present study.

Time frame:
Up to 52 weeks
Reported as:
Count of participants · Participants
Number of Participants With Confirmed True Positive Belimumab Anti-drug Antibodies (ADA)
ParticipantsLong-term Discontinuation GroupTreatment Control GroupTreatment Holiday Group - Holiday PhaseTreatment Holiday Group - Re-start Phase
Negative39291211
Persistent positive0000
Transient positive0000
SecondaryPercentage Change From Baseline in Immunoglobulin

Serum samples were collected at indicated time-points for analysis of immunoglobulins: Immunoglobulin G (IgG), Immunoglobulin A (IgA), and Immunoglobulin M (IgM). Baseline is defined as the Day 0 visit from parent studies. Percentage change from Baseline is equal to 100\* (value at specified visit minus Baseline value) divided by Baseline value.

Time frame:
Baseline (Day 0 from parent studies); Day 0 and 8, 16, 24, 32, 40, 48 and 52 weeks
Reported as:
Median · Percent change
Percentage Change From Baseline in Immunoglobulin
Percent changeLong-term Discontinuation GroupTreatment Control GroupTreatment Holiday Group - Holiday PhaseTreatment Holiday Group - Re-start Phase
IgA,Day 0,n=31,29, 12,0-19.205 (-38.406 to -7.229)-25.909 (-35.168 to -16.901)-22.193 (-33.468 to -14.278)—
IgA,Week 8,n=37,29, 11,0-21.028 (-41.897 to -11.066)-31.455 (-37.166 to -24.186)-24.242 (-36.981 to -14.213)—
IgA, Week 16,n=36,27, 11,0-22.052 (-39.715 to -8.880)-31.016 (-36.676 to -23.432)-20.202 (-38.381 to -4.975)—
IgA, Week 24,n=31,27, 11,0-20.570 (-34.101 to 3.271)-28.000 (-34.097 to -21.033)-21.711 (-35.533 to 5.240)—
IgA, Week 32,n=34,27,0,10-11.243 (-29.004 to 3.004)-29.703 (-37.615 to -19.697)—-23.363 (-39.164 to -1.875)
IgA, Week 40,n=33,25,0,11-10.769 (-33.575 to 2.715)-30.617 (-37.143 to -26.934)—-24.579 (-33.891 to 1.990)
IgA, Week 48,n=33,27,0,10-16.000 (-27.848 to 10.850)-34.091 (-37.867 to -19.767)—-33.936 (-42.105 to 6.883)
IgA, Week 52,n=33,27,0,10-14.859 (-28.646 to 9.346)-30.698 (-38.806 to -17.128)—-31.663 (-40.102 to 0.498)
IgG,Day 0,n=39,29, 12,0-13.939 (-35.349 to 3.571)-29.524 (-35.645 to -14.872)-19.481 (-33.330 to -9.757)—
IgG,Week 8,n=37,29, 11,0-19.169 (-37.209 to -0.877)-29.048 (-35.795 to -6.897)-25.571 (-31.788 to -16.234)—
IgG, Week 16,n=36,27, 11,0-16.169 (-37.881 to 8.306)-29.818 (-35.714 to -5.172)-21.642 (-29.870 to -18.721)—
IgG, Week 24,n=31,27, 11,0-17.982 (-34.545 to 0.662)-26.241 (-32.571 to -7.080)-17.886 (-26.623 to -8.955)—
IgG, Week 32,n=34,27,0,10-9.798 (-34.146 to 3.653)-23.288 (-34.220 to -8.420)—-18.611 (-24.725 to -9.459)
IgG, Week 40,n=34,25,0,11-6.955 (-36.842 to 4.878)-25.532 (-34.286 to -15.575)—-26.484 (-27.473 to -16.418)
IgG, Week 48,n=33,27,0,10-14.063 (-34.082 to 2.222)-25.133 (-33.945 to -6.897)—-20.596 (-29.870 to -8.209)
IgG, Week 52,n=33,27,0,10-11.258 (-34.457 to 9.756)-23.596 (-29.655 to -14.359)—-23.754 (-25.974 to -18.543)
IgM,Day 0,n=31,29, 12,0-47.059 (-67.333 to -26.761)-53.608 (-64.583 to -41.463)-44.326 (-63.895 to -25.516)—
IgM,Week 8,n=37,29, 11,0-49.174 (-65.672 to -34.868)-53.659 (-64.583 to -46.262)-50.943 (-70.621 to -31.325)—
IgM, Week 16,n=36,27, 11,0-50.077 (-61.922 to -30.099)-54.945 (-61.224 to -43.103)-45.926 (-70.690 to -19.277)—
IgM, Week 24,n=31,27, 11,0-39.496 (-53.153 to -36.184)-50.909 (-62.963 to -34.483)-45.161 (-65.517 to -8.511)—
IgM, Week 32,n=34,27,0,10-34.887 (-48.936 to -18.000)-52.577 (-66.667 to -31.250)—-46.548 (-56.863 to -12.766)
IgM, Week 40,n=34,25,0,11-37.870 (-46.847 to -20.667)-52.381 (-65.556 to -41.304)—-48.889 (-67.241 to -10.638)
IgM, Week 48,n=33,27,0,10-31.707 (-54.667 to -11.765)-53.636 (-63.333 to -40.625)—-48.268 (-58.824 to -14.458)
IgM, Week 52,n=33,27,0,10-30.921 (-53.750 to -4.348)-51.648 (-67.532 to -46.429)—-57.966 (-72.414 to -30.120)
SecondaryPercentage Change From Baseline in Autoantibody:Anti-double Stranded Deoxyribonucleic Acid (dsDNA)

Blood samples were collected at indicated time-points for analysis of autoantibodies like dsDNA. Baseline is defined as the Day 0 visit from parent studies. Percentage change from Baseline is equal to 100\* (Value at specified visit minus Baseline value) divided by Baseline value.

Time frame:
Baseline (Day 0 from parent studies); Day 0 and 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52 weeks
Reported as:
Median · Percent change
Percentage Change From Baseline in Autoantibody:Anti-double Stranded Deoxyribonucleic Acid (dsDNA)
Percent changeLong-term Discontinuation GroupTreatment Control GroupTreatment Holiday Group - Holiday PhaseTreatment Holiday Group - Re-start Phase
Day 0,n=39,29,12, 0-82.8 (-90.3 to -38.5)-69.4 (-88.7 to -46.2)-81.3 (-84.9 to -52.0)—
Week 4,n=39,29,12, 0-82.8 (-92.2 to -46.1)-65.9 (-89.0 to -53.8)-83.2 (-90.0 to -51.6)—
Week 8,n=37,29, 11,0-74.3 (-89.5 to -33.7)-70.3 (-89.5 to -47.5)-81.6 (-87.7 to -54.5)—
Week 12,n=38,29, 11,0-77.3 (-89.1 to -28.2)-68.9 (-90.1 to -50.0)-85.0 (-88.6 to -53.0)—
Week 16,n=36,27, 11,0-78.4 (-89.7 to -33.9)-72.8 (-91.2 to -34.1)-79.7 (-86.4 to -64.1)—
Week 20,n=34,27, 11,0-82.8 (-90.3 to -33.7)-70.3 (-91.9 to -50.0)-79.9 (-88.3 to -55.2)—
Week 24,n=31,27, 11,0-82.8 (-92.6 to -41.2)-71.8 (-91.9 to -38.5)-75.0 (-87.4 to -54.5)—
Week 28,n=35,27,0,10-69.8 (-88.9 to -28.1)-72.3 (-91.9 to -46.2)—-79.9 (-88.3 to -56.8)
Week 32,n=34,27,0,11-77.9 (-90.0 to -33.3)-71.4 (-89.5 to -50.0)—-79.6 (-91.3 to -57.1)
Week 36,n=34,27,0,11-75.1 (-88.4 to -13.5)-71.0 (-92.9 to -50.0)—-80.8 (-90.8 to -62.9)
Week 40,n=34,25,0,11-73.6 (-91.2 to -4.8)-87.4 (-93.7 to -70.2)—-79.9 (-90.1 to -53.2)
Week 44,n=34,27,0,10-62.0 (-90.3 to -21.4)-77.7 (-94.0 to -52.3)—-82.5 (-91.1 to -50.0)
Week 48,n=33,27,0,10-71.8 (-90.3 to -21.4)-76.6 (-92.8 to -50.0)—-80.6 (-86.4 to -63.3)
Week 52,n=33,27,0,10-65.3 (-91.7 to -15.9)-78.3 (-91.5 to -38.5)—-79.5 (-91.1 to -64.3)
SecondaryPercentage Change From Baseline in Autoantibody: Antinuclear Antibody (ANA)

Blood samples were collected at indicated time-points for analysis of autoantibodies like ANA. Only participants who had an ANA value measured in INDEX at the parent studies Baseline were included in this analysis. Baseline is defined as the Day 0 visit from parent studies. Percentage change from Baseline is equal to 100\* (Value at specified visit minus Baseline value) divided by Baseline value.

Time frame:
Baseline (Day 0 from parent studies); Day 0 and 24 and 52 weeks
Reported as:
Median · Percent change
Percentage Change From Baseline in Autoantibody: Antinuclear Antibody (ANA)
Percent changeLong-term Discontinuation GroupTreatment Control GroupTreatment Holiday Group - Holiday PhaseTreatment Holiday Group - Re-start Phase
Day 0,n=21,27, 10,0-15.044 (-29.716 to 4.193)-24.938 (-58.221 to 0.000)-32.336 (-47.741 to -26.843)—
Week 24,n=20,26, 10,05.723 (-9.113 to 24.347)-27.434 (-62.747 to 0.000)-29.771 (-44.978 to -13.643)—
Week 52,n=19,26,0,9-16.455 (-56.522 to 21.800)-45.961 (-66.917 to -11.765)—-35.539 (-43.928 to -20.586)
SecondaryPercentage Change From Baseline in Complement Levels

Blood samples were collected at indicated time-points for analysis of complement levels like complement 3 (C3) and complement 4 (C4). Baseline is defined as the Day 0 visit from parent studies. Percentage change from Baseline is equal to 100\* (Value at specified visit minus Baseline value) divided by Baseline value.

Time frame:
Baseline (Day 0 from parent studies); Day 0 and 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52 weeks
Reported as:
Median · Percent change
Percentage Change From Baseline in Complement Levels
Percent changeLong-term Discontinuation GroupTreatment Control GroupTreatment Holiday Group - Holiday PhaseTreatment Holiday Group - Re-start Phase
C3, Day 0,n=39,27,12, 010.3 (-4.5 to 42.9)7.2 (-6.8 to 35.8)32.1 (23.7 to 61.5)—
C3, Week 4,n=39,29,12, 015.4 (-2.2 to 42.0)16.0 (-7.3 to 27.5)14.8 (-6.8 to 46.1)—
C3,Week 8,n=37,29, 11,013.6 (4.3 to 38.3)19.8 (-1.0 to 40.6)31.4 (17.2 to 60.9)—
C3,Week 12,n=38,29, 11,010.9 (-6.3 to 50.0)14.1 (5.2 to 39.1)30.4 (24.7 to 75.0)—
C3,Week 16,n=36,27, 11,015.2 (-0.6 to 59.1)20.5 (0.0 to 46.7)32.2 (20.0 to 62.5)—
C3,Week 20,n=34,27, 11,015.4 (-4.7 to 40.3)13.6 (-4.3 to 26.6)30.0 (18.3 to 70.3)—
C3,Week 24,n=31,27, 11,017.3 (-7.0 to 41.0)19.8 (-1.3 to 58.9)44.2 (5.7 to 53.2)—
C3,Week 28,n=35,27,0,1015.8 (-10.0 to 36.4)15.4 (7.8 to 42.2)—31.3 (12.6 to 57.7)
C3,Week 32,n=34,27,0,1113.8 (0.0 to 53.7)21.6 (6.7 to 50.7)—31.6 (16.0 to 69.2)
C3,Week 36,n=34,27,0,119.4 (-2.9 to 44.8)17.0 (-8.1 to 35.1)—26.0 (11.7 to 67.3)
C3,Week 40,n=34,25,0,1112.8 (-2.5 to 28.3)17.3 (3.1 to 39.7)—41.8 (12.8 to 62.5)
C3,Week 44,n=34,27,0,1014.1 (0.0 to 29.7)22.7 (-6.3 to 51.6)—38.9 (23.0 to 75.0)
C3,Week 48,n=33,27,0,1015.4 (-5.1 to 35.0)15.9 (-4.5 to 41.5)—30.4 (13.8 to 82.7)
C3,Week 52,n=33,27,0,105.9 (-9.1 to 25.9)21.9 (3.5 to 32.8)—36.5 (7.1 to 77.3)
C4, Day 0,n=39,27,12, 036.4 (-6.3 to 100.0)27.8 (11.1 to 128.6)70.8 (25.2 to 154.2)—
C4, Week 4,n=39,29,12, 031.6 (10.0 to 100.0)47.4 (0.0 to 87.5)39.7 (6.7 to 110.4)—
C4,Week 8,n=37,29, 11,037.5 (2.6 to 83.3)71.4 (11.8 to 105.6)58.3 (33.3 to 183.3)—
C4,Week 12,n=38,29, 11,027.6 (4.5 to 122.2)68.4 (12.0 to 121.4)64.3 (16.7 to 200.0)—
C4,Week 16,n=36,27, 11,035.4 (13.1 to 158.3)50.0 (17.4 to 114.3)41.7 (25.0 to 150.0)—
C4,Week 20,n=34,27, 11,032.6 (4.2 to 114.3)64.3 (0.0 to 109.1)58.3 (17.6 to 166.7)—
C4,Week 24,n=31,27, 11,034.8 (0.0 to 128.6)57.1 (15.8 to 125.0)66.7 (26.3 to 83.3)—
C4,Week 28,n=35,27,0,1031.3 (0.0 to 100.0)66.7 (8.0 to 100.0)—50.6 (8.3 to 166.7)
C4,Week 32,n=34,27,0,1127.6 (0.0 to 106.7)92.9 (21.7 to 128.6)—58.3 (21.1 to 175.0)
C4,Week 36,n=34,27,0,1129.2 (0.0 to 100.0)50.0 (11.1 to 116.7)—58.3 (25.0 to 183.3)
C4,Week 40,n=34,25,0,1132.1 (0.0 to 73.3)73.3 (29.4 to 112.5)—58.3 (21.1 to 116.7)
C4,Week 44,n=34,27,0,1020.5 (0.0 to 68.8)57.1 (12.0 to 116.7)—60.7 (36.8 to 150.0)
C4,Week 48,n=33,27,0,1031.3 (-5.9 to 60.0)64.3 (15.8 to 114.3)—34.5 (10.5 to 100.0)
C4,Week 52,n=33,27,0,1017.6 (-5.9 to 62.5)63.2 (-4.0 to 126.7)—58.3 (0.0 to 133.3)
SecondaryPercentage Change From Baseline in B Cell Subsets

Blood samples were collected at indicated time-points for analysis of Activated B cells subsets like Activated CD19+CD20+CD69+, cluster of differentiation 20+ (CD20+), Memory CD19+CD20+CD27+, Naive CD19+CD20+CD27-, Plasma CD19+CD20-CD138+, Plasmacytoid CD19+CD20+CD138+, and SLE Subset CD19+CD38b+CD27b+Lymph. Baseline is defined as the Day 0 visit from parent studies. Percentage change from Baseline is equal to 100\* (Value at specified visit minus Baseline value) divided by Baseline value.

Time frame:
Baseline (Day 0 from parent studies); Day 0 and 8, 16, 24, 32, 40 and 52 weeks
Reported as:
Median · Percent change
Percentage Change From Baseline in B Cell Subsets
Percent changeLong-term Discontinuation GroupTreatment Control GroupTreatment Holiday Group - Holiday PhaseTreatment Holiday Group - Re-start Phase
Memory CD19+CD20+CD27+, Day 0,n=16,2,8,0-69.0 (-80.9 to -58.9)-76.1 (-80.0 to -72.2)-43.2 (-55.0 to 68.3)—
Memory CD19+CD20+CD27+, Week 8,n=15,2,5,0-73.7 (-85.0 to -60.0)-78.9 (-80.0 to -77.8)-50.0 (-71.4 to 50.0)—
Memory CD19+CD20+CD27+,Week16,n=14,2,6,0-83.4 (-93.2 to -66.7)-69.2 (-80.0 to -58.3)-60.7 (-80.0 to 0.0)—
Memory CD19+CD20+CD27+,Week24,n=13,2,6,0-86.7 (-93.3 to -78.3)-59.7 (-69.4 to -50.0)-65.0 (-71.4 to 0.0)—
Memory CD19+CD20+CD27+,Week32,n=12,2,0,7-85.8 (-91.4 to -72.5)-73.3 (-80.0 to -66.7)—-20.0 (-52.0 to 133.3)
Memory CD19+CD20+CD27+,Week40,n=13,2,0,7-80.0 (-84.2 to -73.9)-65.6 (-70.0 to -61.1)—0.0 (-48.0 to 83.3)
Memory CD19+CD20+CD27+,Week52,n=13,2,0,6-81.8 (-86.7 to -65.2)-78.9 (-80.0 to -77.8)—-10.0 (-57.1 to 83.3)
Naive CD19+CD20+CD27-,Day 0,n=16,2,8,0-78.3 (-90.0 to -63.7)-91.6 (-96.9 to -86.3)-81.0 (-91.2 to -27.0)—
Naive CD19+CD20+CD27-,Week 8,n=15,2,5,0-80.5 (-90.4 to -60.0)-94.3 (-96.5 to -92.2)-83.0 (-84.6 to -16.7)—
Naive CD19+CD20+CD27-,Week16,n=14,2,6,0-76.4 (-89.9 to -58.1)-89.6 (-96.9 to -82.4)-81.0 (-92.3 to -10.6)—
Naive CD19+CD20+CD27-,Week 24,n=13,2,6,0-45.7 (-90.3 to 38.1)-92.9 (-95.6 to -90.2)-54.2 (-71.4 to 34.8)—
Naive CD19+CD20+CD27-,Week 32,n=12,2,0,7-39.8 (-68.6 to 93.3)-92.2 (-96.1 to -88.2)—-73.5 (-91.8 to 47.0)
Naive CD19+CD20+CD27-,Week 40,n=13,2,0,7-6.8 (-56.0 to 208.6)-92.6 (-96.9 to -88.2)—-68.4 (-91.2 to 10.6)
Naive CD19+CD20+CD27-,Week 52,n=13,2,0,617.1 (-36.8 to 104.9)-92.7 (-95.2 to -90.2)—-77.9 (-94.3 to 13.6)
Plasma CD19+CD20-CD138+,Day0,n=11,2,8,0-96.2 (-100.0 to -75.6)45.8 (-98.7 to 190.3)-56.7 (-78.4 to 19.8)—
Plasma CD19+CD20-CD138+,Week8,n=10,2,7,0-100.0 (-100.0 to -98.3)752.7 (-96.0 to 1601.4)-88.6 (-92.3 to -44.5)—
Plasma CD19+CD20-CD138+, Week16,n=9,2,7,0-97.8 (-99.3 to -96.5)535.2 (-90.7 to 1161.1)-53.5 (-95.0 to -37.8)—
Plasma CD19+CD20-CD138+,Week24,n=9,2,7,0-88.8 (-99.6 to -74.3)68.9 (-95.5 to 233.3)-79.1 (-88.6 to 844.5)—
Plasma CD19+CD20-CD138+,Week32,n=9,2,0,7-76.0 (-85.9 to -34.1)182.5 (-99.0 to 463.9)—-41.3 (-93.7 to 87.3)
Plasma CD19+CD20-CD138+,Week40,n=9,2,0,7-53.4 (-80.9 to -13.2)-9.0 (-100.0 to 81.9)—-86.5 (-95.7 to 362.8)
Plasma CD19+CD20-CD138+,Week52,n=9,2,0,6-75.5 (-93.7 to -37.9)-43.8 (-100.0 to 12.5)—-53.8 (-91.1 to 60.4)
Plasmacytoid CD19+CD20+CD138+,Day 0,n=11,2,8,0-98.9 (-99.7 to -94.7)118.1 (-85.6 to 321.9)-75.5 (-96.5 to -25.0)—
Plasmacytoid CD19+CD20+CD138+,Week8,n=10,2,7,0-97.6 (-99.8 to -94.6)14.1 (-90.6 to 118.8)-75.0 (-98.2 to 54.9)—
Plasmacytoid CD19+CD20+CD138+,Week16,n=9,2,7,0-98.7 (-100.0 to -96.8)226.3 (-94.4 to 546.9)-75.9 (-95.5 to 526.4)—
Plasmacytoid CD19+CD20+CD138+,Week24,n=9,2,7,0-98.5 (-98.8 to -93.0)-16.3 (-95.0 to 62.5)-15.0 (-65.0 to 254.7)—
Plasmacytoid CD19+CD20+CD138+,Week32,n=9,2,0,7-95.4 (-97.9 to -82.2)-24.1 (-85.6 to 37.5)—-52.5 (-96.3 to 728.3)
Plasmacytoid CD19+CD20+CD138+,Week40,n=9,2,0,7-93.4 (-94.4 to -41.4)-31.3 (-100.0 to 37.5)—2.5 (-94.0 to 52.8)
Plasmacytoid CD19+CD20+CD138+,Week 52,n=9,2,0,6-96.1 (-98.5 to -73.9)202.5 (-91.9 to 496.9)—32.2 (10.0 to 69.8)
SLE Subset CD19+CD38b+CD27b+Lymph,Day0,n=11,2,8,0-28.3 (-60.4 to 43.8)-67.9 (-93.2 to -42.6)-66.7 (-78.1 to 215.2)—
SLE Subset CD19+CD38b+CD27b+Lymph,Week8,n=10,2,7,0-30.5 (-52.0 to 137.2)-91.7 (-96.6 to -86.7)-71.9 (-89.0 to 121.3)—
SLE Subset CD19+CD38b+CD27b+Lymph,Week16,n=9,2,7,021.3 (-82.6 to 157.5)-74.2 (-97.0 to -51.3)-48.6 (-82.1 to 204.4)—
SLE Subset CD19+CD38b+CD27b+Lymph,Week24,n=9,2,7,025.2 (-48.1 to 168.6)-64.7 (-75.1 to -54.2)152.3 (18.0 to 485.1)—
SLE Subset CD19+CD38b+CD27b+Lymph,Week32,n=9,2,0,7-8.4 (-75.9 to 135.1)-37.5 (-82.8 to 7.8)—-4.6 (-93.8 to 305.8)
SLE Subset CD19+CD38b+CD27b+Lymph,Week40,n=9,2,0,7-8.5 (-24.5 to 87.2)-66.3 (-90.6 to -42.1)—-24.6 (-85.3 to 450.6)
SLE Subset CD19+CD38b+CD27b+Lymph,Week52,n=9,2,0,6-23.5 (-54.0 to 20.1)-81.4 (-85.9 to -77.0)—0.7 (-40.8 to 383.0)
CD20+ Day 0,n=16,2,8,0-75.2 (-89.1 to -58.7)-88.1 (-95.8 to -80.5)-77.1 (-86.8 to -22.0)—
CD20+ Week 8,n=15,2,5,0-79.9 (-89.1 to -58.0)-91.0 (-95.8 to -86.2)-80.9 (-81.5 to -11.1)—
CD20+,Week16,n=14,2,6,0-75.4 (-90.5 to -58.7)-84.3 (-96.2 to -72.4)-80.4 (-90.8 to -9.7)—
CD20+,Week24,n=13,2,6,0-52.0 (-90.9 to 26.3)-87.7 (-93.7 to -81.6)-53.4 (-71.3 to 31.9)—
CD20+,Week32,n=12,2,0,7-49.0 (-74.1 to 62.4)-87.4 (-95.4 to -79.3)—-66.2 (-90.1 to 54.2)
CD20+,Week40,n=13,2,0,7-15.2 (-60.0 to 145.6)-86.6 (-96.2 to -77.0)—-59.1 (-88.7 to 16.7)
CD20+,Week52,n=13,2,0,6-12.0 (-45.0 to 88.1)-89.8 (-94.6 to -85.1)—-71.8 (-92.7 to 19.4)
Activated CD19+CD20+CD69+,Day0, n=11,1,8,0-99.8 (-100.0 to -91.7)-86.1 (-86.1 to -86.1)-65.1 (-93.6 to -2.1)—
Activated CD19+CD20+CD69+, Week8, n=10,1,7,0-99.6 (-100.0 to -98.2)-97.1 (-97.1 to -97.1)-76.3 (-100.0 to 2141.7)—
Activated CD19+CD20+CD69+, Week16, n=9,1,7,0-98.9 (-99.4 to -98.3)-93.4 (-93.4 to -93.4)-72.3 (-98.9 to -22.9)—
Activated CD19+CD20+CD69+,Week24, n=9,1,7,0-99.7 (-100.0 to -95.3)-94.2 (-94.2 to -94.2)-50.9 (-95.6 to 80.0)—
Activated CD19+CD20+CD69+,Week32, n=9,1,0,7-98.0 (-99.8 to -97.4)-86.9 (-86.9 to -86.9)—-54.5 (-74.1 to 975.0)
Activated CD19+CD20+CD69+, Week40, n=9,1,0,7-98.1 (-99.8 to -96.7)-100.0 (-100.0 to -100.0)—-47.5 (-100.0 to -24.6)
Activated CD19+CD20+CD69+, Week52, n=9,1,0,6-96.9 (-99.3 to -93.6)-100.0 (-100.0 to -100.0)—-27.4 (-57.5 to 50.0)
SecondaryPercentage Change From 24 Week in B Cell Subsets: Treatment Holiday Group (Re-start Phase)

Blood samples were collected at indicated time-points for analysis of Activated B cells subsets like Activated CD19+CD20+CD69+, CD20+, Memory CD19+CD20+CD27+, Naive CD19+CD20+CD27-, Plasma CD19+CD20-CD138+, Plasmacytoid CD19+CD20+CD138+, and SLE Subset CD19+CD38b+CD27b+Lymph. Percentage change from Week 24 of present study was calculated as 100\*(value at specified visit - Week 24 value) divided by week 24 value. The data below is only reported for the Treatment Holiday Group (Re-start phase). Participants in this group restarted belimumab therapy one day after Week 24, hence the Baseline for this outcome measure was Week 24 visit. No other groups were measured for this outcome.

Time frame:
Week 24, 32, 40 and 52 weeks
Reported as:
Median · Percent change
Percentage Change From 24 Week in B Cell Subsets: Treatment Holiday Group (Re-start Phase)
Percent changeTreatment Holiday Group - Re-start Phase
Memory CD19+CD20+CD27+, Week 32100.0 (40.5 to 250.0)
Memory CD19+CD20+CD27+, Week 4083.3 (48.3 to 366.7)
Memory CD19+CD20+CD27+,Week5266.7 (12.4 to 233.3)
Naive CD19+CD20+CD27-,Week 32-19.0 (-58.8 to 31.1)
Naive CD19+CD20+CD27-,Week 40-12.5 (-61.8 to 7.7)
Naive CD19+CD20+CD27-,Week52-35.6 (-84.8 to -7.9)
Plasma CD19+CD20-CD138+,Week32-16.3 (-71.4 to 237.8)
Plasma CD19+CD20-CD138+, Week40-59.8 (-73.7 to 18.5)
Plasma CD19+CD20-CD138+,Week52-48.0 (-92.4 to 188.9)
Plasmacytoid CD19+CD20+CD138+,Week32-35.7 (-69.3 to 133.5)
Plasmacytoid CD19+CD20+CD138+,Week40-64.3 (-89.4 to -56.9)
Plasmacytoid CD19+CD20+CD138+,Week52-55.0 (-72.7 to -52.1)
SLE SubsetCD19+CD38b+CD27b+Lymph,Week32-55.4 (-71.6 to -27.2)
SLE SubsetCD19+CD38b+CD27b+Lymph,Week40-56.9 (-75.3 to -0.7)
SLE SubsetCD19+CD38b+CD27b+Lymph,Week52-67.2 (-79.7 to -41.0)
CD20+, Week 32-3.3 (-45.2 to 29.7)
CD20+, Week 402.2 (-51.4 to 17.4)
CD20+, Week 52-20.0 (-78.9 to 30.8)
Activated CD19+CD20+CD69+,Week32-28.8 (-75.8 to 64.7)
Activated CD19+CD20+CD69+,Week40-23.8 (-88.1 to 191.2)
Activated CD19+CD20+CD69+,Week52-66.7 (-89.0 to 87.7)
SecondarySELENA SLEDAI Scores Change From Baseline

SELENA SLEDAI assessments consist of 24 individual weighted items in which signs and symptoms, laboratory tests, and physician's assessment for each of 9 organ systems are given a weighted score and summed if present (marked 'Yes') at the time of the visit or in the preceding 10 days. The maximum theoretical score is 105 (all 24 descriptors present simultaneously) with 0 indicating inactive disease (marked 'No'). Data are reported at the specified time-points from Day 0 (of present study) up to Week 52. Baseline is defined as the Day 0 from parent studies. Change from Baseline is equal to (Value at specified visit minus Baseline value).

Time frame:
Baseline (Day 0 from parent studies); Day 0 and 4, 8, 12, 16, 20, 24, 28, 32,36, 40, 44, 48 and 52 weeks
Reported as:
Mean · Scores on a scale
SELENA SLEDAI Scores Change From Baseline
Scores on a scaleLong-term DiscontinuationTreatment Control GroupTreatment Holiday Group - Holiday PhaseTreatment Holiday Group - Re-start Phase
Day 0,n=39,29,12, 0-6.2 ± 4.12-6.9 ± 3.62-6.3 ± 4.31—
Week 4,n=39,29,12, 0-5.9 ± 5.07-6.6 ± 3.44-6.1 ± 4.01—
Week 8,n=38,29, 11,0-6.4 ± 4.18-7.0 ± 3.73-5.9 ± 4.16—
Week 12,n=38,29, 11,0-6.1 ± 4.28-7.0 ± 3.75-6.3 ± 3.95—
Week 16,n=36,27, 11,0-6.4 ± 5.21-6.8 ± 4.05-6.1 ± 3.96—
Week 20,n=36,27, 11,0-6.9 ± 4.17-6.9 ± 3.23-6.1 ± 3.96—
Week 24,n=36,27, 11,0-6.4 ± 4.45-6.7 ± 3.45-5.4 ± 4.01—
Week 28,n=35,27,0,10-5.8 ± 4.22-7.0 ± 3.32—-5.5 ± 5.36
Week 32,n=34,27,0,11-5.7 ± 4.59-7.1 ± 3.38—-6.1 ± 4.01
Week 36,n=34,27,0,11-5.0 ± 4.42-6.7 ± 3.59—-5.9 ± 4.01
Week 40,n=34,27,0,11-5.2 ± 4.30-7.2 ± 3.37—-6.6 ± 4.30
Week 44,n=34,27,0,11-5.8 ± 4.15-7.3 ± 3.49—-6.3 ± 4.65
Week 48,n=33,27,0,11-5.7 ± 4.30-7.3 ± 3.28—-6.1 ± 3.91
Week 52,n=33,27,0,11-5.0 ± 4.39-6.9 ± 3.69—-5.5 ± 4.08
SecondaryNumber of Days of Daily Prednisone Dose >=7.5 mg/Day and/or Increased by 25 Percent From Day 0 of This Study

All corticosteroids are converted to a prednisone equivalent average daily dose (mg/day). The average daily dose at Day 0 was used to assess the relative change in daily dose on a given day. The average daily dose at Day 0 was calculated as sum of the daily dose across all days from the Screening visit date up to and including Day 0 visit date divided by the number of days in the time period. Data reported are the median number of days on which the specified criteria was met for Day 0 to Week 24, Week 24 to Week 52, Day 0 to Week 52. For treatment holiday group, Day 0 to Week 24 corresponds to holiday phase, Week 24 to Week 52 corresponds to treatment Re-start phase.

Time frame:
Day 0 to Week 24; Week 24 to Week 52; Day 0 to Week 52
Reported as:
Median · Days
Number of Days of Daily Prednisone Dose >=7.5 mg/Day and/or Increased by 25 Percent From Day 0 of This Study
DaysLong-term Discontinuation GroupTreatment Control GroupTreatment Holiday Group
Day 0 to Week 24, n=11, 12, 6143.0 (3 to 173)170.0 (67 to 175)168.0 (61 to 170)
Day 0 to Week 52, n=13, 12, 6278.0 (5 to 369)364.0 (145 to 392)364.0 (250 to 366)
Week 24 to Week 52, n=10, 9, 5167.5 (1 to 201)196.0 (189 to 217)196.0 (194 to 196)
SecondaryNumber of Days of Daily Prednisone Dose <=7.5 mg/Day and/or Decreased by 25 Percent From Day 0 of This Study

All corticosteroids are converted to a prednisone equivalent average daily dose (mg/day). The average daily dose at Day 0 was used to assess the relative change in daily dose on a given day. The average daily dose at Day 0 was calculated as sum of the daily dose across all days from the Screening visit date up to and including Day 0 visit date divided by the number of days in the time period. Data reported are the median number of days on which the specified criteria was met for Day 0 to Week 24, Week 24 to Week 52, Day 0 to Week 52. For treatment holiday group, Day 0 to Week 24 corresponds to holiday phase, Week 24 to Week 52 corresponds to treatment Re-start phase.

Time frame:
Day 0 to Week 24; Week 24 to Week 52; Day 0 to Week 52
Reported as:
Median · Days
Number of Days of Daily Prednisone Dose <=7.5 mg/Day and/or Decreased by 25 Percent From Day 0 of This Study
DaysLong-term Discontinuation GroupTreatment Control GroupTreatment Holiday Group
Day 0 to Week 24, n=23,19, 6168.0 (23 to 181)168.0 (26 to 175)166.0 (49 to 170)
Day 0 to Week 52, n=25,19, 6362.0 (23 to 385)364.0 (91 to 391)364.0 (49 to 370)
Week 24 to Week 52, n=24,18, 5195.0 (1 to 208)196.0 (189 to 225)200.0 (189 to 203)

Adverse events

Collected over Non-serious adverse events and serious adverse events (SAE) were collected up to 52 weeks for all treatment groups. For Treatment Control and Treatment Holiday Re-start, it also included 16 weeks follow up after the last dose of belimumab for participants who did not continue in Maintenance phase. For Maintenance phase, non-SAE and SAE were collected until Week 48 of subsequent years (Maintenance is Year 2, 3, 4) and includes 16 weeks follow up after last dose of belimumab.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment Phase: Long-term Discontinuation Group0/39 (0%)6/39 (15.4%)30/39 (76.9%)
Treatment Phase: Treatment Control Group0/29 (0%)2/29 (6.9%)18/29 (62.1%)
Treatment Phase: Treatment Holiday Group - Holiday Phase0/12 (0%)0/12 (0%)7/12 (58.3%)
Treatment Phase: Treatment Holiday Group - Re-start Phase0/11 (0%)1/11 (9.1%)9/11 (81.8%)
Maintenance Phase: Treatment Control0/16 (0%)0/16 (0%)4/16 (25%)
Maintenance Phase: Treatment Holiday0/10 (0%)0/10 (0%)8/10 (80%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventTreatment Phase: Long-term Discontinuation GroupTreatment Phase: Treatment Control GroupTreatment Phase: Treatment Holiday Group - Holiday PhaseTreatment Phase: Treatment Holiday Group - Re-start PhaseMaintenance Phase: Treatment ControlMaintenance Phase: Treatment Holiday
Lumbar vertebral fractureInjury, poisoning and procedural complications0/390/290/121/110/160/10
Lupus nephritisRenal and urinary disorders2/390/290/120/110/160/10
Upper respiratory tract infectionInfections and infestations0/391/290/120/110/160/10
ArthritisMusculoskeletal and connective tissue disorders0/391/290/120/110/160/10
Skin lacerationInjury, poisoning and procedural complications0/391/290/120/110/160/10
Diarrhoea infectiousInfections and infestations1/390/290/120/110/160/10
Pneumonia pseudomonalInfections and infestations1/390/290/120/110/160/10
SepsisInfections and infestations1/390/290/120/110/160/10
Pericarditis lupusCardiac disorders1/390/290/120/110/160/10
Generalised oedemaGeneral disorders1/390/290/120/110/160/10
Most frequent other events
Showing 10 of 72
Most frequent other events
EventTreatment Phase: Long-term Discontinuation GroupTreatment Phase: Treatment Control GroupTreatment Phase: Treatment Holiday Group - Holiday PhaseTreatment Phase: Treatment Holiday Group - Re-start PhaseMaintenance Phase: Treatment ControlMaintenance Phase: Treatment Holiday
NasopharyngitisInfections and infestations10/395/291/124/112/164/10
HypokalaemiaMetabolism and nutrition disorders1/392/291/122/110/160/10
Upper respiratory tract infectionInfections and infestations5/392/292/121/112/161/10
ArthralgiaMusculoskeletal and connective tissue disorders4/392/291/120/110/160/10
ArthritisMusculoskeletal and connective tissue disorders4/390/290/120/110/160/10
Pain in extremityMusculoskeletal and connective tissue disorders4/390/290/120/110/160/10
FatigueGeneral disorders4/390/290/120/110/160/10
Upper respiratory tract infection bacterialInfections and infestations3/390/290/120/110/161/10
CystitisInfections and infestations0/391/290/121/110/161/10
GastroenteritisInfections and infestations1/390/290/121/110/161/10

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Long-term Discontinuation GroupTreatment Control GroupTreatment Holiday GroupTotal
Mean38.9 ± 12.0140.6 ± 9.7638.1 ± 8.0439.4 ± 10.63
Sex: Female, Male
Sex: Female, Male(Participants)Long-term Discontinuation GroupTreatment Control GroupTreatment Holiday GroupTotal
Female3527971
Male4239
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Long-term Discontinuation GroupTreatment Control GroupTreatment Holiday GroupTotal
White/Caucasian/European Heritage9009
Asian: Central/South Asian Heritage1001
Asian: East Asian Heritage2327454
Asian: Japanese Heritage02810
African American/African Heritage5005
Native Hawaiian or Other Pacific Islander1001
08

Study locations

20 sites
  • GSK Investigational Site
    Los Angeles, California 90048, United States
  • GSK Investigational Site
    Manhasset, New York 11030, United States
  • GSK Investigational Site
    Dallas, Texas 75246, United States
  • GSK Investigational Site
    Hefei, Anhui 230001, China
  • GSK Investigational Site
    Suzhou, Jiangsu 215006, China
  • GSK Investigational Site
    Hangzhou, Zhejiang 310009, China
  • GSK Investigational Site
    Beijing, 100032, China
  • GSK Investigational Site
    Beijing, 100044, China
  • GSK Investigational Site
    Chiba, 275-8580, Japan
  • GSK Investigational Site
    Ehime, 791-0295, Japan
  • GSK Investigational Site
    Hokkaido, 060-8604, Japan
  • GSK Investigational Site
    Miyagi, 980-8574, Japan
  • GSK Investigational Site
    Nagasaki, 857-1195, Japan
  • GSK Investigational Site
    Tokyo, 104-8560, Japan
  • GSK Investigational Site
    Tokyo, 162-8655, Japan
  • GSK Investigational Site
    Daegu, 700-721, Korea, Republic of
  • GSK Investigational Site
    Seoul, 110-744, Korea, Republic of
  • GSK Investigational Site
    Seoul, 133-792, Korea, Republic of
  • GSK Investigational Site
    Seoul, Korea, Republic of
  • GSK Investigational Site
    Suwon, Kyonggi-do, 443-721, Korea, Republic of
09

References and documents

Publications

  • Bae SC, Bass DL, Chu M, Curtis P, Dimelow R, Harvey L, Ji B, Kurrasch R, Muzaffar S, Punwaney R, Roth DA, Song YW, Xie W, Zhang F. The effect of 24-week belimumab treatment withdrawal followed by treatment restart in patients with SLE: an open-label, non-randomised 52-week study. Arthritis Res Ther. 2022 Feb 16;24(1):46. doi: 10.1186/s13075-022-02723-y. PubMed 35172878 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2014 to primary completion in Dec 2018, 55 months.

Results were first posted in Jan 2020, 1 year 1 month after primary completion.

Of 53 phase 3 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 84. This study's 55 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2014
First posted
Apr 21, 2014
StartActual
May 13, 2014
Primary completionActual
Dec 14, 2018
CompletionActual
Dec 14, 2018
Results first posted
Jan 31, 2020
Last update
Jan 31, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 31, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02119156
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Apr 21, 2014
Start date
May 13, 2014
Primary completion
Dec 14, 2018
Completion
Dec 14, 2018
Results posted
Jan 31, 2020
Last update
Jan 31, 2020

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Belimumab

Start the discussion